Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)Patisiran Sodium (8.8mg 4.4mL/vial) 30vials,and 53 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jan 21, 2022
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Niigata
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Patisiran Sodium (8.8mg 4.4mL/vial) 30vials
B Pembrolizumab (Genetical Recombination) (100mg 4mL/vial) 1,300vials
C Sugammadex Sodium (200mg 10mL 10vials/case) 300cases
D Gilteritinib Fumarate (40mg 42-
tablets/case) 30cases
E Blinatumomab (Genetical Recombination) (35㎍/vial (with infusion stabilization liquid)) 300vials
F Olaparib (150mg 56tablets/case) 300cases
G Durvalumab (Genetical Recombination) (120mg 2.4mL/vial) 300vials
H Durvalumab (Genetical Recombination) (500mg 10mL/vial) 200vials
I Palivizumab (Genetical Recombination) (100mg 1mL/vial) 400vials
J Benralizumab (Genetical Recombination) (30mg 1mL/syringe) 90syringes
K Risankizumab (Genetical Recombination) (75mg 0.83mL/syringe) 100syringes
L Asfotase alfa (Genetical Recombination) (40mg 1mL/vial) 60vials
M Asfotase alfa (Genetical Recombination) (80mg 0.8mL/vial) 300vials
N Eculizumab (Genetical Recombination) (300mg 30mL/vial) 100vials
O Ravulizumab (Genetical Recombination) (300mg 30mL/vial) 200vials
P Adalimumab (Genetical Recombination) (40mg 0.4mL/syringe) 500syringes
Q Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30-
tablets/vial) 400vials
R Mepolizumab (Genetical Recombination) (100mg 1mL/kit) 300kits
S Eftrenonacog Alfa (Genetical Recombination) (3,000IU/vial (with solution)) 50vials
T Nusinersen Sodium (12mg 5mL/vial) 9vials
U Methotrexate (1,000mg 40mL/vial) 700vials
V Dasatinib Hydrate (50mg 30tablets/case) 90cases
W Lenalidomide Hydrate (5mg 40-
capsules/case) 100cases
X Abatacept (Genetical Recombination) (250mg/vial) 500vials
Y Ipilimumab (Genetical Recombination) (50mg 10mL/vial) 100vials
Z Cetuximab (Genetical Recombination) (100mg 20mL/vial) 2,200vials
AA Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL/syringe) 600syringes
AB Romiplostim (Genetical Recombination) (250㎍/vial) 300vials
AC Aflibercept (Genetical Recombination) (2mg 0.05mL/syringe) 500syringes
AD Tirabrutinib Hydrochloride (80mg 28tablets/case) 200cases
AE Nivolumab (Genetical Recombination) (240mg 24mL/vial) 900vials
AF Paclitaxel (100mg/vial) 700vials
AG Palonosetron hydrochloride (0.75mg 50m l5bags/case) 600cases
AH Denosumab (Genetical Recombination) (120mg 1.7mL/vial) 900vials
AI Tocilizumab (Genetical Recombination) (80mg 4mL/vial) 1,500vials
AJ Tocilizumab (Genetical Recombination) (200mg 10mL/vial) 1,400vials
AK Tocilizumab (Genetical Recombination) (162mg 0.9mL/kit) 1,700kits
AL Bevacizumab (Genetical Recombination) (100mg 4mL/vial) 2,200vials
AM Bevacizumab (Genetical Recombination) (400mg 16mL/vial) 1,800vials
AN Satralizumab (Genetical Recombination) (120mg 1mL/syringe) 50syringes
AO Atezolizumab (Genetical Recombination) (1,200mg 20mL/vial) 200vials
AP Pertuzumab (Genetical Recombination) (420mg 14mL/vial) 400vials
AQ Emicizumab (Genetical Recombination) (150mg 1mL/vial) 20vials
AR Rituximab (Genetical Recombination) (500mg 50mL/vial) 200vials
AS Lanreotide Acetate (120mg/syringe) 80syringes
AT Ustekinumab (Genetical Recombination) (45mg 0.5mL/syringe) 300syringes
AU Golimumab (Genetical Recombination) (50mg 0.5mL/kit) 300kits
AV Infliximab (Genetical Recombination) (100mg/vial) 3,200vials
AW Ramucirumab (Genetical Recombination) (100mg 10mL/vial) 300vials
AX Ramucirumab (Genetical Recombination) (500mg 10mL/vial) 90vials
AY Polyethylene glycol treated human normal immunoglobulin (10g 100mL/vial) 600vials
AZ Cabozantinib Malate (20mg 30-
tablets/case) 100cases
BA Brentuximab Vedotin (Genetical Recombination) (50mg/vial) 80vials
BB Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g/vial (with soluation)) 1,300vials
⑷ Delivery period : From 1 April, 2022 through 31 March, 2023
⑸ Delivery place : Niigata University Medical and Dental Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A or Grade B qualification during fiscal 2021 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
⑺ Time limit of tender : 17 : 15 15 March, 2022
⑻ Contact point for the notice : Yukiyo Aoyama, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951-8520 Japan, TEL 025-227-2430
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.